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In schizophrenia, previous stereological post-mortem investigations of anterior,
posterior, and total hippocampal subfields showed no alterations in total neuron number
but did show decreased oligodendrocyte numbers in CA4, an area that corresponds to
the polymorph layer of the dentate gyrus (DG). However, these investigations identified
oligodendrocytes only on the basis of morphological criteria in Nissl staining and did
not assess alterations of interneurons with immunohistochemical markers. Moreover,
the association of findings in the posterior hippocampus with cognitive deficits remains
unknown. On the basis of the available clinical records, we compared patients
with definite and possible cognitive dysfunction; nine patients had evidence in their
records of either definite (n = 4) or possible (n = 5) cognitive dysfunction. Additionally,
we assessed the density of two oligodendrocyte subpopulations immunostained
by the oligodendrocyte transcription factors Olig1 and Olig2 and of interneurons
immunolabeled by parvalbumin. We investigated posterior hippocampal subregions in
the post-mortem brains of the same schizophrenia patients (SZ; n = 10) and healthy
controls (n = 10) we examined in our previously published stereological studies. Our
stereological studies found that patients with definite cognitive deficits had decreased
total/Nissl-stained oligodendrocyte numbers in the left (p = 0.014) and right (p = 0.050)
CA4, left CA2/3 (p = 0.050), left CA1 (p = 0.027), and left (p = 0.050) and right
(p = 0.014) subiculum of the anterior part of the hippocampus compared to patients
with possible cognitive deficits. In the present study, we found no significant influence of
definite cognitive deficits in the posterior part of the hippocampus, whereas in the entire
hippocampus SZ with definite cognitive deficits showed decreased oligodendrocyte
numbers in the left (p = 0.050) and right (p = 0.050) DG and left CA2/3 (p = 0.050). We
did not find significant differences in Olig1-, Olig2-, or parvalbumin-positive cell density
between SZ and controls in any of the subregions of the posterior hippocampus.
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Based on the results from our stereological study we hypothesize that a decreased
number of oligodendrocytes in the anterior and entire hippocampus may be involved
in cognitive deficits by impairing the connectivity of this structure in schizophrenia. In the
posterior hippocampus, we could not replicate previously reported findings of decreased
interneurons from the entire hippocampus.
Keywords: schizophrenia, hippocampus, oligodendrocytes, interneurons, cognition, immunohistochemistry,
post-mortem
INTRODUCTION
Schizophrenia has an unfavorable outcome in more than half of
all patients and is linked to social and vocational disability (an der
Heiden and Häfner, 2011). This unfavorable outcome is mainly
due to negative symptoms, including cognitive dysfunction.
While positive symptoms can be treated well by antipsychotics
when given according to current guidelines (Hasan et al.,
2012), effective treatment options for negative symptoms are
still lacking. In this context, a recent meta-analysis revealed
that cognitive dysfunction and residual negative symptoms are
widely resistant to any known treatment (Fusar-Poli et al., 2015).
Another meta-analysis, however, showed that antipsychotics
have at least a moderate effect on cognitive impairments in
schizophrenia (Desamericq et al., 2014). Cognitive impairments
in schizophrenia involve deficits in episodic and working
memory, for example, as well as in attention, processing speed,
and problem solving (Nuechterlein et al., 2004; Falkai et al.,
2011).
A cognitive cluster representing diminished verbal memory
is related to decreased volume of the hippocampus (Geisler
et al., 2015). Interestingly, in schizophrenia these verbal
memory deficits have been found to be correlated with
a loss of hippocampal volume, especially on the left side
(Hasan et al., 2014). Recent examination of structural
magnetic resonance imaging-based alterations in hippocampal
subfields revealed decreased volumes of the cornu ammonis
(CA) CA4/dentate gyrus (DG), CA2/3, and subiculum in
schizophrenia patients (SZ) compared to healthy controls
(Haukvik et al., 2015), but underlying alterations on the
cellular level and their relationship to cognitive deficits remain
unknown.
Recently, our group investigated the cytoarchitecture of the
posterior, anterior, and entire hippocampus in post-mortem
schizophrenia brains by evaluating neuronal, oligodendrocyte,
and astrocyte numbers with design-based stereological
estimation. In the posterior area, we found a significant
reduction of oligodendrocyte numbers in the left and right
CA4 regions (Schmitt et al., 2009). In the anterior part, we
found a decreased number of oligodendrocytes in the left CA4,
fewer neurons in the left DG, and smaller volumes of both
the left CA4 and DG in SZ compared to healthy controls.
In the entire hippocampus, both decreased oligodendrocyte
numbers in the left CA4 and reduced volume remained
significant (Falkai et al., 2016). In the Nissl-stained brain
sections, however, we identified oligodendrocytes on the basis
of morphological criteria only and did not distinguish between
pyramidal neurons and interneurons. This approach may
be relevant to our results, because in a stereological study,
somatostatin-stained interneurons have been reported to be
reduced in CA4, CA2/3, and CA1 and parvalbumin-stained
interneurons in CA4 and CA1, although the total number of
neurons was unchanged (Konradi et al., 2011). Moreover, the
clinical consequence of our findings and the involvement of
a deficit of premature or mature oligodendrocytes remains
unknown. Oligodendrocytes are involved in myelination and
ensure proper connectivity in neuronal networks. In SZ, deficits
in myelination and brain connectivity have been found (Cassoli
et al., 2015; Saia-Cereda et al., 2015), which are hypothesized
to be related to symptoms of the disease and cognitive deficits
(Mitterauer, 2011). In fact, in diffusion tensor imaging (DTI)
studies verbal memory has been reported to be associated
with decreased left-side dominant fractional anisotropy in the
hippocampus and fornix of SZ (Lim et al., 2006; Nestor et al.,
2007).
The aim of the present study was to address the question
whether the findings of this study and those of our previous
stereological studies in the anterior, posterior, and entire
hippocampus (Schmitt et al., 2009; Falkai et al., 2016) can
be connected to simple measures of cognitive dysfunction
in this illness. Furthermore, we investigated whether the
density of more premature oligodendrocytes, stained by
the oligodendrocyte transcription factors Olig1, or of more
mature oligodendrocytes stained by Olig2 respectively, or of
parvalbumin-positive interneurons is altered in the posterior part
of the hippocampus in the same post-mortem schizophrenia
brains as previously investigated by design-based stereology in
histologically stained sections (Schmitt et al., 2009; Falkai et al.,
2016).
MATERIALS AND METHODS
Participant Characteristics
Post-mortem brains were obtained from the Düsseldorf Brain
Collection (Bogerts et al., 1990) and the use of post-mortem
material has been approved by the Ethics Committee of
University of Magdeburg. Patients fulfilled ICD-9 criteria for
schizophrenia and had been treated with typical antipsychotics
for most of their illness. Exclusion criteria were alcohol or drug
abuse and other neuropsychiatric disorders. We investigated
the same sample as in our previously published stereological
study of the posterior hippocampus in schizophrenia (Schmitt
et al., 2009). Briefly, we assessed 10 patients with schizophrenia
(mean [SD] age 55.1 [7.7] years; five males, five females;
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TABLE 1 | Characteristics of healthy controls and schizophrenia patients (SZ) and healthy controls investigated in the present study of the posterior
hippocampus.
Schizophrenia patients
No. S A D C CPE Cause of death Last neuroleptic treatment
P3 M 48 18 2 3500 Cardiac failure Haloperidol, Haldoperidol Decanoate, Zuclopenthixol
P9 M 65 26 1 540 Pulmonary insufficiency Haloperidol, Fluphenazine
P10 M 46 18 1 250 Pulmonary embolism Clozapine, Levomepromazine
P14 M 51 28 2 350 Ileus Perphenazine, Promethazine
P20 M 47 23 2 640 Cardiac arrest Fluphenazine, Benperidol, Levomepromazine
P7 F 66 30 1 800 Myocardial infarction Benperidole, Fluphenazine
P12 F 53 20 2 2495 Myocardial infarction Perphenazine, Pericyazine
P13 F 60 16 1 0 Pneumonia Fluphenazine
P18 F 63 23 1 988 Suicide Haloperidol
P23 F 52 28 n.a. n.a. Suicide by drowning n.a.
Healthy controls
N29 M 47 Coronary thrombosis
N20 M 64 Aneurysm rupture
N3 M 56 Pancreatitis
N10 M 50 Myocardial infarction
N23 M 38 Myocardial infarction
N34 F 64 Peritonitis
N22 F 47 Renal failure
N27 F 50 Aneurysm rupture
N21 F 52 Ovarial carcinoma
N19 F 33 Coronary thrombosis
S = Gender (M = male, F = female), A = age at death (years), D = duration of disease, C = Cognitive deficits: 1 = possible cognitive deficits, 2 = definite cognitive deficits,
CPE = dose of neuroleptics (mg/day) in chlorpromazine equivalents, n.a.= no data available.
mean [SD] post-mortem interval [PMI] 42.0 [17.2] h; mean
[SD] disease duration: 23.0 [4.9] years) and 10 age- and
gender-matched healthy controls without a history of a
neuropsychiatric disorder, alcohol or drug abuse, dementia,
neurological illness, trauma, or chronic terminal disease (mean
[SD] age 50.2 [10.1] years; 5 males, 5 females; mean [SD] PMI
36.8 [20.3] h; Table 1). The mean daily dose of neuroleptic
treatment during the last 90 days had been documented and
calculated in chlorpromazine equivalents (CPE; Rey et al.,
1989). Brains were uniformly fixed in toto in 10% phosphate
buffered paraformaldehyde for about 7 months (pH 7.0,
t = 15–20◦C). Then, the frontal and occipital parts of the
brain were separated from the middle part, which was located
between the lateral geniculate nucleus and the splenium of
the corpus callosum, i.e., containing the anterior and posterior
hippocampus. From this middle part, 20 µm coronal sections
containing both hemispheres were cut on a Polycut S Leica
microtome. The thickness of each section was determined
by focusing through the section and subtracting the z-axis
coordinate of the lower from that of the upper surface by
the microcator, part of the Olympus microscope. The mean
(SD) section thickness after histological procedure was 18.7
(1.1) µm.
Within the hippocampus, we analyzed two sections per brain,
taken from the posterior part of the hippocampal formation,
which spanned from the lateral geniculate nucleus to the level
of the splenium of the corpus callosum. The subregions to be
investigated separately were the CA1, CA2/3, and CA4 (deep
polymorph layer of the DG), and subiculum. CA2 and CA3 were
lumped together as described in the literature because these small
regions are difficult to separate at the microscopic level (Schmitt
et al., 2009).
Immunohistochemistry
Immunohistochemical staining was prepared as described
previously (Mosebach et al., 2013). Briefly, sections were
deparaffinized, and antigen demasking was performed by
boiling the sections for 4 min in 10 mM citrate buffer
(pH 6.0). Sections were then preincubated with 1.5% H2O2
for 10 min to block endogenous peroxidase activity. Non-
specific binding sites were blocked with 10% normal goat
serum for 60 min and washings with Phosphate buffered saline
(PBS) buffer. Monoclonal mouse anti-Olig1 antibody (R&D
Systems, Abingdon, UK, dilution 1:50) or rabbit anti-Olig2
antibody (Millipore/Merck Darmstadt, Germany, dilution 1:150)
was applied for 72 h at 4◦C for immunostaining of Olig1-
or Olig2-positive oligodendrocytes, respectively. Then, the
streptavidin-biotin technique was used to incubate sections with
a biotinylated anti-mouse (GE Healthcare, Freiburg, Germany,
dilution 1:100) or anti-rabbit (DakoCyomation, Glostrup,
Denmark, dilution: 1:100) antibody, respectively. Chromogen
3,3’-diaminobenzidine (DAB) and ammonium nickel sulfate
were used to visualize the reaction product. Parvalbumin-
positive interneurons were immunolabeled under the same
conditions with a monoclonal antibody to the protein (Sigma,
Taufkirchen, Germany; dilution 1:500) and an anti-mouse
peroxidase secondary antibody (Biozol, Germany, dilution 1:50;
Bernstein et al., 2007).
Evaluation of Olig1-, Olig2- and
Parvalbumin-Stained Sections
A rater blinded to diagnosis analyzed the regions of interest in
both hemispheres at 400×magnification by using a stereological
workstation consisting of a modified light microscope (BX50;
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FIGURE 1 | Representative high-power photomicrographs of
20 µm-thick coronal sections from a schizophrenia patient (SZ)
(C,E,G,I) and a healthy control (A,B,D,F,H). (A) Overview of subregions
including cornu ammonis (CA) 1, 2–3, 4, dentate gyrus (DG) and subiculum
(Sub) in a Nissl and myelin stained section. The following sections show CA4.
(B,C) White arrowheads indicate neurons, black arrowheads point to
oligodendrocytes. (D,E) Olig1 immunostained stained section with black
arrowheads showing oligodendrocytes. (F,G) Olig2 immunolabeled section
with black arrowheads showing oligodendrocytes. (H,I) Parvalbumin stained
section with asterisks pointing to immunopositive neurons.
Olympus, Tokyo, Japan), Olympus Uplan Apo objectives
(1.5×, 20×, 50×, 100× oil), motorized specimen stage for
automatic sampling, electronic microcator, CCD color video
camera, PC with frame grabber board, stereology software
(Stereoinvestigator, MBF Bioscience Williston, VT, USA), and
17’’ monitor. Boundaries of hippocampal subfields were traced
on video images displayed on the computer screen, and volumes
were calculated in both sections. The numerical cell density of
Olig1-, Olig2-, and parvalbumin-stained cells (Figure 1) was
measured in the subregions by using the optional dissector
and expressed as cells/mm3. Because the actual mean (SD)
thickness of the sections was 18.7 (1.1) µm, two well-defined
optical planes within the sections were used (distance 16 µm
between the upper and lower guard zones), and all stained
cells that came into focus while passing from the upper to the
lower optical plane (plane of the dissector) were counted. The
individual volume shrinkage factors (VSF) were calculated from
the measured linear shrinkage factor (LSF) with the following
formula: VSF = (LSF) (Mosebach et al., 2013). The intra-class
correlation coefficients for intra-rater reliability were 0.81 for
Olig1, 0.95 for Olig2, and 0.83 for the parvalbumin-stained
cells.
Evaluation of Cognitive Deficits in
Schizophrenia Patients (SZ)
In our correlation analysis, we used results from Nissl-
stained serial section of the anterior and posterior part of
the hippocampus (Schmitt et al., 2009; Falkai et al., 2016).
We searched for a surrogate marker of cognitive dysfunction
in the group of SZ. Therefore, an independent psychiatrist
(J. Steiner) who was blind to the histological results evaluated
the medical records and used a three-point semi-quantitative
scale to rate patients’ level of cognitive deficits (0 = no cognitive
deficits, 1 = possible cognitive deficits, 2 = definite cognitive
deficits). The rater searched for descriptions of deficits in
the domains of attention, verbal learning, working memory,
and executive functions and for indications of a decrease in
cognitive performance or increase in residual symptoms over
time. Patients who clearly had any of these symptoms were
defined as having definite cognitive deficits; and those with
marginal or borderline symptoms, possible cognitive deficits.
Nine patients had either definite (n = 4) or possible (n = 5) deficits
(Table 1); no records were available for one patient. It was not
possible to formalize this kind of classification by scales (Ortakov
et al., 1999).
Statistical Analysis
The significance level was α = 0.05, and all tests were two-tailed.
Statistical analyses were performed with IBM SPSS statistics 22.
In the first analysis, outcome measures were densities from
immunohistochemical Olig1, Olig2, and parvalbumin stainings
in the hippocampal subfields CA1, CA2/3, CA4, and the
subiculum. The independent factor was diagnostic group (SZ,
controls). Because Levene’s test detected significant variance
inhomogeneities between the groups, we used non-parametric
Mann-Whitney U tests to analyze diagnostic group differences.
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FIGURE 2 | Left column (A–E): Number of oligodendrocytes [×105] in SZ with definite and possible cognitive deficits in anterior hippocampus: DG
(DG, (A)), CA4 (B), CA2/3 (C), CA1 (D), and subiculum (Sub, (E)). Columns represent mean oligodendrocyte number, and bars represent standard error of the
mean. Light gray columns: left hemisphere; dark gray columns: right hemisphere. Decreased oligodendrocyte number in SZ with definite cognitive deficits were
observed in CA4 (left and right), CA2/3 (left), CA1 (left), and subiculum (left and right). Middle column (F–J): Number of oligodendrocytes [×105] in SZ with definite
and possible cognitive deficits in posterior hippocampus: DG (F), CA4 (G), CA2/3 (H), CA1 (I), and Sub (J). Columns represent mean oligodendrocyte number,
(Continued)
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FIGURE 2 | Continued
and bars represent standard error of the mean. Light gray columns: left hemisphere; dark gray columns: right hemisphere. No significant differences were found
between patients with definite and possible cognitive deficits. Right column (K–O): Number of oligodendrocytes [×105] in SZ with definite and possible cognitive
deficits in entire (anterior + posterior) hippocampus: DG, (K), CA4 (L), CA2/3 (M), CA1 (N), and Sub (O). Columns represent mean oligodendrocyte number, and
bars represent standard error of the mean. Light gray columns: left hemisphere; dark gray columns: right hemisphere. Decreased oligodendrocyte numbers in SZ
with definite cognitive deficits were observed in DG (left and right) and CA2/3 (left). ∗p < 0.05.
Cell densities were correlated with age at death, PMI, dose of
neuroleptic treatment in CPE and disease duration by means of
Spearman correlations for the total sample and separately for SZ
and controls.
In addition to densities of oligodendrocytes and interneurons,
outcome measures of the second analysis were the number of
oligodendrocytes and neurons, estimated stereologically, and the
structure volumes in the subfields (CA1, CA2/3, CA4, DG, and
subiculum) of the anterior, posterior, and entire hippocampus of
SZ, as published in Falkai et al. (2016). The independent factor
was cognitive deficits (definite or possible). Means, standard
deviations, and standard errors of the mean were calculated for
all outcome measures for left and right hemispheres separately.
We applied Levene’s test of variance homogeneity to compare
the two groups with different degrees of cognitive deficits.
Because this test found significant variance inhomogeneities
for several variables, patients with definite and possible
deficits were compared with non-parametric Mann-Whitney U
tests.
For this explorative study with small group sizes, especially
as regards the analysis of the influence of cognitive deficits on
cell numbers or densities within the group of SZ, the results are
presented without error probability correction. If a Bonferroni
adjustment of the type I error probability had been applied, no
significant differences would remain between SZ and controls.
However, if the error probability was adjusted the power of
detecting existing mean differences would be too low.
RESULTS
Impact of Cognitive Deficits on Total
Oligodendrocyte Numbers (Nissl Staining)
Our simple classification of cognitive deficits indicated that
patients with a definite cognitive dysfunction had a more
pronounced reduction of oligodendrocyte total cell numbers
(combined staining with cresyl violet (Nissl) and myelin (luxol
fast blue), Schmitt et al., 2009; Falkai et al., 2016) than
patients with only a possible cognitive deficit. In the anterior
hippocampus, SZ patients with definite cognitive deficits showed
significantly lower numbers of oligodendrocytes in the left CA1
(−40%, p = 0.027), left CA2/3 (−40%, p = 0.050), left (−45%,
p = 0.014) and right (−25%, p = 0.050) CA4, and left (−48%,
p = 0.050) and right (−52%, p = 0.014) subiculum. In the
posterior part of the hippocampus, definite cognitive deficits
appeared to have no significant influence, while in the entire
hippocampus SZ patients with definite cognitive deficits showed
decreased oligodendrocyte numbers in the left (−42%, p = 0.050)
and right (−41%, p = 0.050) DG and left CA2/3 (−35%, p = 0.050;
Figure 2). In patients with definite cognitive dysfunction, the
number of neurons was not significantly lower in the DG of the
anterior, posterior, or entire hippocampus (Figure 3). However,
it has to be noted that patients with definite cognitive deficits
had received a higher daily dose of neuroleptics during the last
90 days expressed in CPE compared to patients with only a
possible cognitive deficit (1906 ± 1333 vs. 388 ± 302 mg/day,
p = 0.032).
Densities of Olig1-, Olig2- and
Parvalbumin-Positive Cells
We did not find significant differences between SZ and controls
in any of the subregions of the posterior hippocampus in
the number of Olig1-, Olig2-, or parvalbumin-positive cells.
However, in the SZ we found trends towards a decrease in
Olig1-positive oligodendrocytes in the right CA2/3 (−57%,
p = 0.070), right CA4 (−54%, p = 0.096), and right subiculum
(−39%, p = 0.082). The SZ and controls showed no significant
differences with respect to the mean densities of Olig2-positive
oligodendrocytes in the investigated subregions of the posterior
part of the hippocampus, but the density of parvalbumin-stained
interneurons was increased in the left CA1 region in the SZ
(+124%, p = 0.033) and showed a trend towards an increase in
the right CA4 (+175%, p = 0.067; see Figure 4).
In the total sample of SZ and healthy controls, females
showed higher Olig1 cell densities than males in the left (+138%,
p = 0.009) and right (+126%, p = 0.005) CA1, left CA2/3 (+201%,
p = 0.008), and left CA4 (+47%, p = 0.026) subregions. With
respect to Olig2-stained cells, females had increased cell densities
in the left (+54%, p = 0.011) and right (+52%, p = 0.004) CA1,
left (+61%, p = 0.007) and right (+69%, p = 0.006) CA2/3,
and left subiculum (+33%, p = 0.007). Furthermore, females
had an increased density of parvalbumin-positive interneurons
compared tomales in the left (+192%, p = 0.016) and right (+92%,
p = 0.032) CA2/3, and left subiculum (+169%, p = 0.033; see
Figure 5).
In healthy controls, age correlated negatively with the density
of Olig1-positive cells in the left CA2/3 (rho =−0.743, p = 0.035)
and right CA4 (rho = −0.671, p = 0.034), whereas in SZ
no significant correlations between age and cell densities were
observed. In controls, the PMI correlated with oligodendrocyte
density (Olig1, CA1 right: rho = 0.715, p = 0.020, CA2/3 left:
rho = 0.749, p = 0.033), but not with Olig2 or interneuron density.
No significant correlations of Olig1-, Olig2- or interneuron
densities with disease duration were observed. The Olig2 density
correlated with CPE in the right subiculum (rho = 0.833,
p = 0.010), but no other correlations with dose of neuroleptic
treatment had been found (Figure 6).
Furthermore, the densities of Olig1-, Olig2-, and
parvalbumin-stained cells did not differ between patients
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FIGURE 3 | Number of neurons [×105] in (A) anterior, (B) posterior, and (C) entire DG in SZ patients with definite and possible cognitive deficits.
Columns represent means, and bars represent standard error of the mean.
with definite and possible cognitive deficits in any of these areas
of the posterior hippocampus.
DISCUSSION
Our recent design-based stereology investigation of the posterior
part of the hippocampus in post-mortem schizophrenia brains
revealed a significant bilateral reduction of oligodendrocytes
in the left and right CA4 regions (Schmitt et al., 2009). In
a subsequent study, we evaluated the anterior part of the
hippocampus in the same cases and calculated results for the
entire hippocampus. This study replicated the reduction of
oligodendrocyte numbers, but only for the left CA4 region
in schizophrenia (Falkai et al., 2016). Noteworthy is that no
other histological components, including neurons and astroglia,
showed alterations in the anterior or posterior portion of
the hippocampus in schizophrenia, which is in contrast to
the reduction of interneurons in schizophrenia found in a
stereological study of the hippocampus and published also
in reviews (Konradi et al., 2011; Heckers and Konradi,
2015). However, the study by Konradi et al. (2011) provided
stereological data. Also, our evaluation of cell densities may have
more methodological bias based on effects of tissue shrinkage
which is caused by fixation or staining procedures.
To connect the reduction of oligodendrocytes with clinical
outcome, we used the available case notes to subdivide the
SZ into those with definite or possible cognitive dysfunction.
Nine of the 10 patients showed either definite or possible
deficits. Of interest is that on the basis of our stereological
data we found a relation between definite cognitive dysfunction
and reduced oligodendrocytes in several subregions of the
anterior and entire hippocampus, which might point to a
central role of oligodendrocytes in cognitive dysfunction in
schizophrenia. Oligodendrocytes are important in myelination
and are an integral part of the connectome, which allows
brain regions to communicate with each other efficiently and
quickly (Cassoli et al., 2015). Therefore, we hypothesize that a
reduction in oligodendrocytes in the hippocampus might well
be an underlying psycho-architectural substrate of cognitive
dysfunction in schizophrenia. The fornix, which comprises
the white matter tract of the hippocampus, shows decreased
fractional anisotropy in first-episode and chronic SZ (Rametti
et al., 2009; Abdul-Rahman et al., 2011; Kunimatsu et al.,
2012; Fitzsimmons et al., 2014), and these alterations in
the fornix correlate with impairment in declarative-episodic
memory (Kuroki et al., 2006; Lim et al., 2006). Moreover,
oligodendrocyte-related gene variants are related to white matter
tract integrity and cognitive performance in SZ and healthy
controls (Voineskos et al., 2013). Our results and those findings
frommagnetic resonance imaging studies support the hypothesis
of structural and functional disconnectivity in a hippocampal-
medial prefrontal network, leading to profound cognitive deficits
in schizophrenia (Hutcheson et al., 2015).
Because in our stereological studies (Schmitt et al., 2009;
Falkai et al., 2016), Nissl staining allows oligodendrocytes to
be distinguished only morphologically from interneurons, we
used Olig1, Olig2, and parvalbumin to stain sections adjacent
to those in the same brains previously evaluated by design-
based stereology. In accordance with our findings of unchanged
neuron numbers in the Nissl-staining stereological study, we
found no difference between schizophrenia and healthy controls
in the density of a subgroup of 20% of interneurons stained
by parvalbumin in the posterior part of the hippocampus
(Freund and Buzsaki, 1996). This is in contrast to previously
reported reductions of the total number of parvalbumin-
positive interneurons in CA4 and CA1 and the density of
parvalbumin-stained interneurons in CA2 (Benes et al., 1998;
Knable et al., 2004) or all subfields (Zhang and Reynolds,
2002). However, these studies have conflicting results with
respect to the affected subregions, and they did not separate
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FIGURE 4 | Left column (A–D): Cell density (cells/mm3 × 103) in CA4 (A), CA2/3 (B), CA1 (C), and subiculum (Sub, [D]) of Olig1-positive
oligodendrocytes in SZ patients and controls. Columns represent mean cell density, and bars represent standard error of the mean. Light gray columns: left
hemisphere; dark gray columns: right hemisphere. Middle column (E–H): Cell density (cells/mm3 × 103) in CA4 (E), CA2/3 (F), CA1 (G), and Sub (H) of
Olig2-positive oligodendrocytes in SZ and controls. Columns represent mean cell density, and bars represent standard error of the mean. Light gray columns: left
hemisphere; dark gray columns: right hemisphere. Right column (I–L): Cell density (cells/mm3 × 103) in CA4 (I), CA2/3 (J), CA1 (K), and Sub (L) of
parvalbumin-positive interneurons in SZ and controls. Columns represent mean cell density, and bars represent standard error of the mean. Light gray columns: left
hemisphere; dark gray columns: right hemisphere. Increased density of parvalbumin-stained cells in SZ compared to controls was observed in left CA1. ∗p < 0.05.
the anterior from the posterior part of the hippocampus.
Moreover, two-dimensional counting of cell density in only a
few sections without considering the volume of the region has
methodological limitations because of the influence of volume
differences and tissue shrinkage resulting from fixation and
staining procedures. Bias may be caused also by cutting of
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FIGURE 5 | Left column (A–D): Cell density (cells/mm3 × 103) in CA4 (A), CA2/3 (B), CA1 (C), and subiculum (Sub, [D]) of Olig1-positive
oligodendrocytes in male and female subjects in the posterior hippocampus. Columns represent mean cell density, and bars represent standard error of the
mean. Light gray columns: left hemisphere; dark gray columns: right hemisphere. Increased Olig1-positive oligodendrocytes in females compared to males were
observed in left and right CA1, in left CA2/3 and in left CA4. ∗p < 0.05. Middle column (E–H): Cell density (cells/mm3 × 103) in CA4 (E), CA2/3 (F), CA1 (G), and
subiculum (H) of Olig2-positive oligodendrocytes in males and females in the posterior hippocampus. Columns represent mean cell density, and bars represent
standard error of the mean. Light gray columns: left hemisphere; dark gray columns: right hemisphere. Increased density of Olig2-positive oligodendrocytes in
females compared to males were observed in left and right CA1, left and right CA2/3 and in left subiculum (Sub) ∗p < 0.05. Right column (I–L): Cell density
(cells/mm3 × 103) in CA4 (I), CA2/3 (J), CA1 (K), and subiculum (L) of parvalbumin-positive interneurons in males and females in the posterior hippocampus.
Columns represent mean cell density, and bars represent standard error of the mean. Light gray columns: left hemisphere; dark gray columns: right hemisphere.
Increased density of parvalbumin-stained cells in females compared to males has been detected in left and right CA2/3 and in left subiculum (Sub) ∗p < 0.05.
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FIGURE 6 | Upper section (A–B): scatterplots showing the relation between age and Olig1 densities in CA2/3 left (A) and in CA4 right (B). Middle section
(C–D): scatterplots showing the relation between post mortem interval (PMI) and Olig1 densities in CA1 right (C) and CA2/3 left (D). Bottom (E): scatterplot showing
the relation between chlorpromazine equivalents (CPE) and Olig2 density in the right subiculum. Control subjects appear as dark circles, SZ appear as light squares.
cells during sectioning, non-random orientation, and irregular
cell shape and size (Williams and Rakic, 1988). Therefore,
design-based stereological studies of the posterior part of
the hippocampus are necessary to elucidate the impact of
decreased inhibition by a marked deficit of subclasses of
interneurons.
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Although the reduction of Olig1-positive oligodendrocytes
in CA4 did not reach significance, the trend towards significant
reduction is in the same direction as in our stereological study
and partly supports the notion of reduced oligodendrocyte
numbers in the posterior part of the hippocampus in
schizophrenia (Schmitt et al., 2009; Falkai et al., 2016).
Oligodendrocytes stained by Olig1 represent myelinating
and oligodendrocyte progenitors (Arnett et al., 2004), and
immunolabeling with other oligodendrocyte markers such as
2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP), GalC or
myelin basic protein (MBP) is necessary to investigate possible
myelin damage or whether more mature forms of these glia cells
are altered in schizophrenia.
A limitation of our study is that it was only possible to
identify cognitive deficits by evaluating medical records, and
no structured neuropsychological in vivo test results were
available. However, the rater (J. Steiner) is an experienced
psychiatrist, and case notes were detailed, because of the
long-term hospitalization of the patients. In addition, the
sample size was small and, because we did not perform
Bonferroni correction, results should be replicated in an
independent sample. Prospective post-mortem studies that
use standardized tests to investigate cognitive deficits in
brain donors before death also are warranted to confirm
our results. A further limitation is the long-term treatment
with typical neuroleptics, which may have influenced our
results. The patient group with definite cognitive deficits had
received higher doses compared to patients with only possible
cognitive deficits. However, from clinical practice it is known
that patients with persisting symptoms receive higher doses
of antipsychotics than patients in remission. Additionally,
neuroleptic treatment may have influenced cell densities in our
study. Haloperidol is known to increase expression of Olig2
in the hippocampus and cerebral cortex, whereas quetiapine
and olanzapine increase expression of both Olig1 and Olig2
(Wang et al., 2010; Fang et al., 2013). Additionally, haloperidol
and clozapine have been shown to be protective for energy-
deprived immature oligodendrocytes (Steiner et al., 2011).
Moreover, after cuprizione-induced demyelination, quetiapine
enhanced oligodendrocyte regeneration and myelin repair
(Zhang et al., 2012). Thus, the unchanged density of Olig1-
and Olig2-positive cells in the SZ in our study may be a
consequence of increased expression of oligodendrocytes due
to long-term antipsychotic treatment, which counteracted the
decreased expression of oligodendrocytes previously reported
in these patients (Schmitt et al., 2009; Falkai et al., 2016).
Moreover, the high variance in the data for the SZ may
be due to treatment with different neuroleptics. However,
because some variances in density were significantly higher in
controls than in SZ, e.g., Olig1 densities in CA2/3 and CA4
(compare Figure 4) it would be speculative to explain this high
variance by the type of antipsychotic medication and dosage.
In addition, the density of parvalbumin-positive interneurons
may also have been affected by treatment, because risperidone
has been found to normalize loss of this cell population after
prenatal immune activation in rats (Piontkewitz et al., 2012).
However, in healthy animals haloperidol and clozapine did
not change the density of parvalbumin-stained interneurons
(Cahir et al., 2005). Finally, age may have influenced our
results, because we found a negative correlation between age
and Olig1 density in CA4 and CA2/3; however, this correlation
was found only in healthy controls and not in SZ. We detected
a clear gender effect on cell densities, but this is irrelevant
for our group comparisons because there were equal numbers
of males and females in both the schizophrenia and control
groups.
In summary, we could show that a loss of oligodendrocytes
in the anterior and entire hippocampus is related to cognitive
deficits in this patient group. However, we did not find
significant differences in Olig1-, Olig2-, or parvalbumin-positive
cell densities in any subregions of the posterior hippocampus
in SZ compared to healthy controls. Here, we did find a
trend towards a reduction of Olig1-stained cells in CA4, which
points in the same direction as the decrease of oligodendrocyte
number in this area in schizophrenia found in our previous
stereological studies (Schmitt et al., 2009; Falkai et al., 2016).
Further studies investigating white matter tract integrity of
the posterior hippocampus and its relationship to cognitive
deficits and oligodendrocyte gene variants are needed to
further illustrate the impact of oligodendrocyte dysfunction on
cognition in schizophrenia. Furthermore, animalmodels of gene-
environment interaction may elucidate the relationship between
oligodendrocyte loss and cognitive deficits.
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